Abstract
Given the rates of pathological gambling and its impact on affected individuals and their relatives, effective treatments are needed. There are, however, no approved pharmacological treatments for pathological gambling. This paper describes the development of pharmacological treatments for pathological gambling and is based on a review of the literature published in the past 10 years. Important studies were carried-out on antidepressants, mood stabilizers, and antipsychotic agents. In the absence of comorbid psychiatric disorder, these studies did not conclude to the efficacy of these psychotropic drugs. A possible efficacy of opiate antagonist treatment for pathological gambling has been replicated in a number of placebo-controlled studies. Preliminary results on N-acetyl cysteine, Memantine and Topiramate produced significant improvement for pathological gamblers and may open new avenues for treatment.
Keywords: Pathological gambling, drugs, antidepressant, lithium, valproate, carbamazepine, naltrexone, nalmefene, topiramate, glutamate, N-acetylcysteine, gambling, antiepileptic, nefazodone, fluvoxamine, paroxetine, sertraline, cyclothymia, olanzapine
Current Pharmaceutical Design
Title: Psychopharmacological Treatment in Pathological Gambling: A Critical Review
Volume: 17 Issue: 14
Author(s): Sophia Achab and Yasser Khazaal
Affiliation:
Keywords: Pathological gambling, drugs, antidepressant, lithium, valproate, carbamazepine, naltrexone, nalmefene, topiramate, glutamate, N-acetylcysteine, gambling, antiepileptic, nefazodone, fluvoxamine, paroxetine, sertraline, cyclothymia, olanzapine
Abstract: Given the rates of pathological gambling and its impact on affected individuals and their relatives, effective treatments are needed. There are, however, no approved pharmacological treatments for pathological gambling. This paper describes the development of pharmacological treatments for pathological gambling and is based on a review of the literature published in the past 10 years. Important studies were carried-out on antidepressants, mood stabilizers, and antipsychotic agents. In the absence of comorbid psychiatric disorder, these studies did not conclude to the efficacy of these psychotropic drugs. A possible efficacy of opiate antagonist treatment for pathological gambling has been replicated in a number of placebo-controlled studies. Preliminary results on N-acetyl cysteine, Memantine and Topiramate produced significant improvement for pathological gamblers and may open new avenues for treatment.
Export Options
About this article
Cite this article as:
Achab Sophia and Khazaal Yasser, Psychopharmacological Treatment in Pathological Gambling: A Critical Review, Current Pharmaceutical Design 2011; 17 (14) . https://dx.doi.org/10.2174/138161211796150774
DOI https://dx.doi.org/10.2174/138161211796150774 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Propofol: Therapeutic Indications and Side-Effects
Current Pharmaceutical Design The Trigeminocardiac Reflex as Oxygen Conserving Reflex in Humans: Its Ischemic Tolerance Potential
Vascular Disease Prevention (Discontinued) Multivariate Statistical Tools for the Evaluation of Proteomic 2D-maps:Recent Achievements and Applications
Current Proteomics Cellular Balance, Genes,and the Huang Ti Nei Ching Su Wen
Current Neurovascular Research “Tripping out” with the TRP Superfamily and TRPV1 for Novel Neuroprotection
Current Neurovascular Research Donepezil Derivatives Targeting Amyloid-β Cascade in Alzheimer's Disease
Current Alzheimer Research Small Heat Shock Proteins and Protein-Misfolding Diseases
Current Pharmaceutical Biotechnology Sleep Disturbance is Associated with Incident Dementia and Mortality
Current Alzheimer Research Neuropathological Correlates of Falling in the CC75C Population-Based Sample of the Older Old
Current Alzheimer Research Vitexin with its Derivatives is Responsible for the Cholinomimetic Properties of <i>Penianthus longifolius</i> Extract which Stimulates Muscarinic Receptors
The Natural Products Journal Neuroprotective Effects of Exercise Treatments After Injury: The Dual Role of Neurotrophic Factors
Current Neuropharmacology Erythropoietin and Oxidative Stress
Current Neurovascular Research The Underestimated Role of Mechanical Stimuli in Brain Diseases and the Relate d In Vitro Models
Current Pharmaceutical Design Stroke in Women - Oral Contraception, Pregnancy, and Hormone Replacement Therapy
Current Vascular Pharmacology Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases
Current Topics in Medicinal Chemistry Repetitive Transcranial Magnetic Stimulation Reverses Aβ1–42-induced Dysfunction in Gamma Oscillation during Working Memory
Current Alzheimer Research Dementia After Age 75: Survival in Different Severity Stages and Years of Life Lost
Current Alzheimer Research Personalized Medicine, Bioethics and Social Responsibilities: Re-thinking the Pharmaceutical Industry to Remedy Inequities in Patient Care and International Health
Current Pharmacogenomics and Personalized Medicine Depression and Vascular Disease: Conceptual Issues, Relationships and Clinical Implications
Vascular Disease Prevention (Discontinued) Age-Related Neurodegeneration Prevention Through mTOR Inhibition: Potential Mechanisms and Remaining Questions
Current Topics in Medicinal Chemistry